Sym004 is a 1:1 mixture of two recombinant human-mouse chimeric monoclonal antibodies (mAb), targeting non-overlapping EGFR epitopes (mAb992 and mAb1024). This compound facilitates the rapid internalization of EGFR and mediates subsequent degradation of internalized receptors through EGFR cross-linking. Sym004 can be utilized in research concerning metastatic colorectal cancer, head and neck cancer (H&N), and lung cancer.